Accuray's Fiscal 2026 Q1 Results Review
Madison, WI, Accuray Incorporated (NASDAQ: ARAY), has recently shared its financial outcomes for the first quarter ending September 30, 2025. Despite facing challenges, the company is firmly committed to its innovative path and strategic overhaul.
Highlights of the Quarter
In a notable update on October 20, 2025, Accuray revealed significant transformation efforts that include:
- Appointment of Steve La Neve as the new President and Chief Executive Officer, succeeding Suzanne Winter, who will continue as an advisor until November 2025.
- Steve La Neve is collaborating with Board member Steven F. Mayer, who has been appointed as the Transformation Board Sponsor to spearhead strategic initiatives.
This leadership transition is expected to guide the company towards a renewed operational focus that aligns with its strategic vision.
Restructuring Plan and Financial Performance
During this first quarter, Accuray launched a restructuring plan aimed at cutting costs and aligning resources with strategic goals. The company recorded $2.8 million in restructuring expenses, prominently featuring $1.5 million due to severance and $1.3 million in related consulting services.
Accuray introduced the Accuray Stellar™ Solution, particularly within the U.S. market, showcasing this new configuration of the Radixact® Treatment Delivery System at a recent ASTRO meeting. Additionally, a memorandum of understanding was signed with the University of Wisconsin School of Medicine to enhance online adaptive radiotherapy.
Financial Overview
Accuray's total net revenue for the first quarter stood at $93.9 million, reflecting a 7% decline compared to $101.5 million in the same quarter of the previous fiscal year. Within this, product revenue decreased by 23%, amounting to $37.2 million, while service revenue saw a 7% uptick to $56.8 million.
The gross profit was noted at $26.5 million, accounting for 28.3% of total revenue, contrasting with a gross profit of $34.5 million (33.9%) year-over-year. The downward pressure on gross margins resulted from the company's geographical sales mix and impact from joint venture accounting.
Expense Profile
The operating expenses for the quarter reached $37.9 million, up by 3% versus $36.6 million from the prior year. Notably, the first quarter included $2.4 million attributed to restructuring and an additional $0.4 million in unusual financing costs. If these expenses were excluded, operating costs would have actually dropped by 4% compared to last year.
Unfortunately, the company reported a net loss of $21.7 million, translating to $0.18 per share, compared to a net loss of $4.0 million and $0.04 per share the previous year. The adjusted EBITDA stood at a loss of $4.1 million compared to a positive $3.1 million previously.
Orders and Future Guidance
Gross product orders were $39.6 million, down from $55.4 million year-over-year. The book-to-bill ratio held stable at 1.1 for both quarters. Important to note is that the order backlog reached $395.7 million by the end of September, a decrease of around 16% from the previous year.
As for cash reserves, Accuray had $63.9 million in cash, cash equivalents, and short-term restricted cash, an increase of $5.9 million since the end of June 2025.
For the entire fiscal year 2026, Accuray is maintaining a revenue guidance range of $471 million to $485 million and anticipates adjusted EBITDA in the $31 million to $35 million bracket.
Investors' Call and Closing Remarks
Accuray’s management will address stakeholders during a conference call to discuss these results along with recent developments. Interested parties can access this call through the company's Investor Relations section on its website, with full details also available for replay post-event.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is dedicated to advancing radiation therapy technology to enhance patient care globally. The company specializes in innovative solutions that cater to complex healthcare needs, facilitating a quicker recovery process for patients in oncology, neuro-radiosurgery, and more.
Frequently Asked Questions
What recent changes occurred in Accuray's leadership?
Steve La Neve has been appointed as the new President and CEO, succeeding Suzanne Winter.
What was Accuray's total revenue for the first quarter?
Accuray’s total net revenue for Q1 of fiscal 2026 was $93.9 million.
How did Accuray manage its restructuring costs?
The company incurred $2.8 million in restructuring charges, focusing on aligning resources and reducing costs.
What are the projected revenues for fiscal year 2026?
Accuray expects total net revenues to range from $471 million to $485 million.
How did adjusted EBITDA perform for this quarter?
Adjusted EBITDA for the first quarter was reported as a loss of $4.1 million.
